All In Biotech

Drug Trial Radar · NCT04592653

Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)

Clinical and Immunologic Activity of Nemvaleukin Alfa With Less Frequent IV Dosing Schedule as Monotherapy and in Combination With Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumor Patients - ARTISTRY-3

Last checked: Nov 19, 2026Latest source record: Jun 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

78

Planned (sponsor's estimate)

Start

Sep 30, 2020

Primary completion

Jul 2024

Study completion Dec 2024

Sponsor

Lead sponsor
Mural Oncology, IncIndustry
Sponsor type
Industry
First posted
Oct 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will be conducted in 2 cohorts. A single-center design for the tumor microenvironment (TME) cohort (Cohort 1), and a multicenter design for the less frequent intravenous (IV) dosing cohort (Cohort 2).

Conditions

  • Advanced Solid Tumor

Interventions

  • Nemvaleukin alfaBiological

    IV infusion over 30 minutes

  • PembrolizumabBiological

    IV infusion over 30 minutes

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in density (cell counts per mm2) of immune cell (including total T cells, CD8+ T cells, CD56+ cells and Treg cells)Time frame: From the time of the Patient's pre-treatment biopsy to the time of the Patient's on-treatment biopsy
  2. Changes in ratios (including T/Treg, CD8+/Treg, CD56+/Treg) based on immunohistochemistry (IHC) and/or immunofluorescence (IF) in the TME between pretreatment and on-treatment (Cycle 2 Day 8) paired tumor biopsiesTime frame: From the time of the Patient's pre-treatment biopsy to the time of the Patient's on-treatment biopsy
  3. Incidence of dose-limiting toxicity (DLT)Time frame: From the first dose through end of dose-limiting toxicity observation period (up to 24 months)

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • START Midwest

    Grand Rapids, Michigan

  • MD Anderson Cancer Center

    Houston, Texas

  • START Mountain

    West Valley City, Utah

  • NEXT Virginia

    Fairfax, Virginia

  • Hospital Clinico San Carlos

    Madrid, Spain

  • CIOCC HM Sanchinarro

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.